| A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma (NCT07687914) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2026-07-23 |
| A Study of IMM0306 in IgG4-Related Disease (NCT07621939) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2026-07-01 |
| IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma (NCT07355283) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2026-02-01 |
| A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors (NCT07170787) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2025-10-15 |
| A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women (NCT07118085) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2025-08-18 |
| A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (NCT06788431) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2025-03-10 |
| A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer (NCT06746870) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2024-12-01 |
| IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) (NCT06647862) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2024-11-11 |
| A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors (NCT06764836) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2024-07-23 |
| A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma (NCT06465446) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2024-06-01 |
| A Study Of IMM47 In Subjects With Advanced Solid Tumors (NCT05985083) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2023-08-18 |
| A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide (NCT05771883) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2023-05-01 |
| IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors (NCT05780307) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2023-03-23 |
| IMM40H Phase I Dose Escalation and Expansion (NCT05549557) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-09-01 |
| IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors (NCT05076591) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-06-20 |
| Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor (NCT05235438) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-06-15 |
| Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas (NCT05833984) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-05-17 |
| IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 (NCT05805956) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-02-15 |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05140811) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-01-05 |
| IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors (NCT05972460) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2021-08-18 |
| Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) (NCT04746131) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2021-01-15 |
| Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma (NCT05805943) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2020-03-02 |